Qiagen’s (QGEN) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Qiagen (NYSE:QGEN) in a report published on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has a $52.00 target price on the stock, down from their prior target price of $55.00.

A number of other brokerages have also recently weighed in on QGEN. Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the stock a “hold” rating in a research note on Thursday, June 25th. Citigroup reaffirmed a “neutral” rating and issued a $45.00 target price (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. Robert W. Baird increased their target price on Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday. UBS Group assumed coverage on Qiagen in a report on Wednesday, September 9th. They set a “neutral” rating and a $47.00 target price on the stock. Finally, Barclays set a $40.00 price target on Qiagen and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $44.43.

Qiagen Stock Performance

Shares of QGEN stock opened at $50.42 on Thursday. The stock has a market capitalization of $10.39 billion, a PE ratio of 25.83, a price-to-earnings-growth ratio of 5.01 and a beta of 0.61. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The stock’s 50-day moving average price is $44.44 and its 200 day moving average price is $40.64. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same quarter in the prior year, the firm earned $0.60 EPS. Qiagen’s quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities research analysts forecast that Qiagen will post 2.44 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hilltop National Bank acquired a new stake in Qiagen during the second quarter worth about $50,000. Integrated Wealth Concepts LLC bought a new position in Qiagen in the second quarter worth about $59,000. Allworth Financial LP boosted its stake in Qiagen by 20.8% in the second quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after acquiring an additional 317 shares during the period. denkapparat Operations GmbH acquired a new position in Qiagen in the second quarter valued at approximately $105,000. Finally, EverSource Wealth Advisors LLC boosted its stake in Qiagen by 46.8% in the first quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after acquiring an additional 876 shares during the period. Institutional investors own 70.00% of the company’s stock.

Key Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.